DrugPatentWatch Database Preview
INGREZZA Drug Profile
Which patents cover Ingrezza, and what generic alternatives are available?
Ingrezza is a drug marketed by Neurocrine and is included in one NDA. There are three patents protecting this drug.
This drug has thirty-two patent family members in eighteen countries.
The generic ingredient in INGREZZA is valbenazine tosylate. One supplier is listed for this compound. Additional details are available on the valbenazine tosylate profile page.
Summary for INGREZZA
| International Patents: | 32 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 21 |
| Patent Applications: | 15 |
| Drug Prices: | Drug price information for INGREZZA |
| DailyMed Link: | INGREZZA at DailyMed |
Generic Entry Opportunity Date for INGREZZA
Generic Entry Date for INGREZZA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for INGREZZA
| Drug Class | Vesicular Monoamine Transporter 2 Inhibitor |
| Mechanism of Action | Vesicular Monoamine Transporter 2 Inhibitors |
Synonyms for INGREZZA
| (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl L-valinate |
| (2R,3R,11bR)-9,10-Dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H- benzo(a)quinolizin-2-yl L-valinate |
| (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester |
| [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl] (2S)-2-amino-3-methylbutanoate |
| 1025504-45-3 |
| 54K37P50KH |
| AKOS027321089 |
| AS-35294 |
| CHEMBL2364639 |
| CS-5908 |
| D10675 |
| DB11915 |
| EX-A2002 |
| GEJDGVNQKABXKG-CFKGEZKQSA-N |
| GTPL8694 |
| HY-16771 |
| L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester |
| MolPort-044-723-889 |
| NBI 98854 |
| NBI-98854;NBI98854;NBI 98854 |
| SB17456 |
| SCHEMBL15932979 |
| UNII-54K37P50KH |
| Valbenazine |
| Valbenazine (USAN/INN) |
| Valbenazine [USAN:INN] |
| Valbenazine pound NBI-98854 pound(c) |
| ZINC43195697 |
US Patents and Regulatory Information for INGREZZA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-001 | Apr 11, 2017 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-002 | Oct 4, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-001 | Apr 11, 2017 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for INGREZZA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Israel | 258732 | Start Trial |
| South Korea | 101500766 | Start Trial |
| Japan | 5290185 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
